CDK4/6-IN-3 is primarily used in cancer research as a potent inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). These kinases play a crucial role in regulating cell cycle progression, particularly in the transition from the G1 phase to the S phase. By inhibiting CDK4/6, this compound can effectively halt the proliferation of cancer cells, making it a valuable tool in studying and developing targeted cancer therapies. It is often utilized in preclinical studies to evaluate its efficacy in various cancer models, including breast cancer, where CDK4/6 inhibitors have shown significant promise. Additionally, CDK4/6-IN-3 is employed in mechanistic studies to better understand the pathways involved in cell cycle regulation and tumor growth, aiding in the design of more effective therapeutic strategies.